Investment Decisions Based on Biosimilar Programs, Part 2

Posted 22 August 2013 By Raymond A. Huml, MS, DVM, RAC, Kamali Chance, MPH, PhD, RAC, Allen R. Baum, JD, and Eileen Provost

This article is the second part of a two-part series examining the environment for third-party capital providers interested in investing in biosimilars. It describes three hurdles facing potential investors: access to capital, exclusivity and intellectual property and commercialization.

Share this article:

Tags:

Regulatory Exchange: Latest Updates From the Community